Health · NASDAQ · USD · Data as of 2026-05-16
AUM
$32.14M
Expense ratio
0.60%
Yield
1.24%
YTD return
+2.94%
Last price
$33.84
Broad Equity · Coverage 75% · low
Today
79.8
Outlook
57.2
Block A (composite-derived)
49.4
Block C (market behavior)
99.9
Today overlay (Block D)
0.0
Outlook overlay (Block D)
0.0
today_score = clip(0,100, 50 + 0.15·(A−50) + 0.60·(C−50) + D_today). Block B (holdings rollup) is in Phase 3 development; β=0 caps the natural range at ~12.5–87.5 in Preview v0.9. Formula version tide-etf-v1.0.0.
49.4
Coverage 75% · medium
Liquidity
—
Expenses
45.0
Performance
—
Volatility
25.9
Dividend
45.0
Concentration
25.0
Smart Money
69.6
Activist
100.0
Formula version composite-v1.0.0. Axes hover to see why a sub-score is missing.
First Trust Nasdaq Pharmaceuticals ETF (FTXH) is an exchange-traded fund from First Trust in the Mixed asset class. Launched in 2016. Assets under management: 32,144,676.
Bullish Whales composite rating: 49 out of 100. Evidence coverage 75% across 6 of 8 axes. Strongest axes: activist exposure, smart-money flow, expenses.
Annualized one-year realized volatility 17%, classified moderate. Weakest axes: concentration, volatility.
Top-10 weight 1%, diversified, led by BMY. Trailing yield 0%.
etf_composite_score_current · activist_score, composite_score, concentration_score, confidence, coverage_pct, expenses_score, smart_money_score, volatility_scoreetf_fundamentals_td · dividend_frequency, yieldetf_holdings_top10 · holding_symbol, weightetf_universe · asset_class, aum_usd, fund_type, inception_date, issuer, name, ticker, volatility_1yThe First Trust NASDAQ Pharmaceuticals ETF is an exchange-traded fund that invests primarily in the pharmaceutical sector, providing investors with exposure to a broad array of companies involved in developing, producing, and marketing drugs and pharmaceuticals. This ETF seeks to track the NASDAQ US Smart Pharmaceuticals Index, which is designed to follow companies that exhibit certain growth characteristics and are poised for increased market activity within the sector. By focusing on pharmaceuticals, this ETF plays a crucial role in the health care segment of the financial market, appealing to investors interested in gaining focused exposure to this dynamic and essential industry. It encompasses firms involved in various stages of pharmaceutical production, from early-stage biotech firms to established large-cap drug manufacturers, thereby offering a diverse portfolio within its sector. The ETF provides a passive investment approach, allowing investors to capitalize on the pharmaceutical industry's overall performance without the need for active management or individual stock selection. Its market significance lies in offering a specialized investment vehicle for tracking the growth and trends in this critical industry, which consistently demands innovation and adapts to global health needs.
Net AUM change history is not yet available for this ETF. Fund-flow time series is a Phase B deliverable.
Current AUM: $32,144,676. AUM change is computed from rolling daily fundamentals snapshots; it reflects total net-asset deltas (creations/redemptions + market value moves), not pure share creations.
Fund documents (fact sheets, prospectuses, semi-annual reports) for FTXH are coming soon. The BW fund-document archive will surface PDFs alongside a metadata index for searchability.